RxDoctor Payments Data

Jeffrey Bidinger, MD

Dermatology · Chillicothe, OHNPI 1437130044

Payments from drug & device makers

$8,287in general payments, 2019–2025

Across 378 payments — averaging $21.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$959
  • Novartis$798
  • E.r. Squibb & Sons, L.L.C.$789
  • Sun Pharmaceutical Industries Inc.$726
  • Sanofi$420
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$8,20299%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,287 in reported general payments places this provider in the 75th percentile of 460 dermatology providers in Ohio.

See all dermatology providers in Ohio

Medicare billing

Part B allowed, 2024
$158,520
Medicare patients
733
Services billed
2,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa14$297,041
Dupixent PenDupilumab49$215,154
OtezlaApremilast14$150,806
Cosentyx Sensoready (2 Pens)Secukinumab14$132,228
RinvoqUpadacitinib13$82,062
OlumiantBaricitinib12$64,378
Clobetasol Propionate128$9,553
Tacrolimus33$4,588
Ketoconazole107$1,949
Halobetasol Propionate14$1,621
ValacyclovirValacyclovir Hcl21$1,309
Fluorouracil21$1,292
Triamcinolone Acetonide108$1,017
Minocycline Hcl17$731
Lovastatin12$561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$295$150,80614 claims
AbbVieRinvoq$2,694$82,06213 claims
Lilly USA, LLCOlumiant$384$64,37812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 460 dermatology providers in Ohio.

Other dermatology in Chillicothe

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →